Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy

References

• Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012;136:795–804. doi:10.1007/s10549-012-2315-y.
   PubMed Web of Science ®Google Scholar
• Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sanchez V, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232–245. doi:10.1158/2159-8290.CD-13-0286.
   PubMed Web of Science ®Google Scholar
• Dotto GP, Weinberg RA, Ariza A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A. 1988;85:6389–6393. doi:10.1073/pnas.85.17.6389.
   PubMed Web of Science ®Google Scholar
• Rudnick JA, Arendt LM, Klebba I, Hinds JW, Iyer V, Gupta PB, Naber SP, Kuperwasser C. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One. 2011;6:e24605. doi:10.1371/journal.pone.0024605.
   PubMed Web of Science ®Google Scholar
• Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet. 2006;2:e119. doi:10.1371/journal.pgen.0020119.
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe F, Itohara S,Werb Z, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–744. doi:10.1038/35036374.
   PubMed Web of Science ®Google Scholar
• Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, DiPrete B, Betz KS, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257–272. doi:10.1016/j.ccr.2011.01.020.
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1454. doi:10.1093/jnci/djm135.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73. doi:10.1038/nri2216.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215–233. doi:10.1038/nrd3626.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–867. doi:10.1200/JCO.2011.41.0902.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611–618. doi:10.1093/annonc/mdt556.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51. doi:10.1016/j.cell.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Tu E, Chia PZ, Chen W. TGFbeta in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev. 2014;25:423–435. doi:10.1016/j.cytogfr.2014.07.014.
   PubMed Web of Science ®Google Scholar
• Kelly PM, Davison RS, Bliss E, McGee JO. Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer. 1988;57:174–177. doi:10.1038/bjc.1988.36.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao Y-W, Wei Y-Q. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2012;7:e50946. doi:10.1371/journal.pone.0050946.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang XH, Zhao YX, Chen C, Xu XY, Sun Q, Wu H-Y, Chen M, Sang J-F, Su L, et al. Cancer-associated fibroblasts correlate with tumor-associated macrophages infiltration and lymphatic metastasis in triple negative breast cancer patients. J Cancer. 2018;9:4635–4641. doi:10.7150/jca.28583.
   PubMed Web of Science ®Google Scholar
• Lacalle RA, Blanco R, Carmona-Rodriguez L, Martin-Leal A, Mira E, Manes S. Chemokine receptor signaling and the hallmarks of cancer. Int Rev Cell Mol Biol. 2017;331:181–244.
   PubMed Web of Science ®Google Scholar
• Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. 2017;6:2115–2125. doi:10.1002/sctm.17-0138.
   PubMed Web of Science ®Google Scholar
• Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012;1:717–725. doi:10.4161/onci.20068.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16:176. doi:10.1186/s12943-017-0742-4.
   PubMed Web of Science ®Google Scholar
• Velaei K, Samadi N, Barazvan B, Soleimani Rad J. Tumor microenvironment-mediated chemoresistance in breast cancer. Breast. 2016;30:92–100. doi:10.1016/j.breast.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Naik A, Al-Zeheimi N, Bakheit CS, Al Riyami M, Al Jarrah A, Al Moundhri MS, Al Habsi Z, Basheer M, Adham SA. Neuropilin-1 associated molecules in the blood distinguish poor prognosis breast cancer: a cross-sectional study. Sci Rep. 2017;7:3301. doi:10.1038/s41598-017-03280-0.
   PubMed Web of Science ®Google Scholar
• Oh N, Park JI, Park JH, Kim KS, Lee DR, Park KS. The role of ELK3 to regulate peritumoral lymphangiogenesis and VEGF-C production in triple negative breast cancer cells. Biochem Biophys Res Commun. 2017;484:896–902. doi:10.1016/j.bbrc.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, Greve B, El-Shinawi M, Mohamed MM, Götte M, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer. 2017;16:57. doi:10.1186/s12943-017-0621-z.
   PubMed Web of Science ®Google Scholar
• Fertig EJ, Lee E, Pandey NB, Popel AS. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Sci Rep. 2015;5:12133. doi:10.1038/srep12133.
   PubMed Web of Science ®Google Scholar
• Jin K, Pandey NB, Popel AS. Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget. 2017;8:60210–60222. doi:10.18632/oncotarget.19417.
   PubMedGoogle Scholar
• Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun. 2014;5:4715. doi:10.1038/ncomms5715.
   PubMed Web of Science ®Google Scholar
• Dore-Savard L, Lee E, Kakkad S, Popel AS, Bhujwalla ZM. The Angiogenic Secretome in VEGF overexpressing breast cancer xenografts. Sci Rep. 2016;6:39460. doi:10.1038/srep39460.
   PubMed Web of Science ®Google Scholar
• Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res. 2018;20:54. doi:10.1186/s13058-018-0981-3.
   PubMed Web of Science ®Google Scholar
• Norton KA, Jin K, Popel AS. Modeling triple-negative breast cancer heterogeneity: effects of stromal macrophages, fibroblasts and tumor vasculature. J Theor Biol. 2018;452:56–68. doi:10.1016/j.jtbi.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Lee E, Pandey NB, Popel AS. Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clin Exp Metastasis. 2013;31:67–79. doi:10.1007/s10585-013-9610-9.
   PubMed Web of Science ®Google Scholar
• Lee E, Pandey NB, Popel AS. Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. Expert Rev Mol Med. 2015;17:e3. doi:10.1017/erm.2015.2.
   PubMed Web of Science ®Google Scholar
• Lee E, Lee SJ, Koskimaki JE, Han Z, Pandey NB, Popel AS. Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Sci Rep. 2014;4:7139. doi:10.1038/srep07139.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. doi:10.1172/JCI45014.
   PubMed Web of Science ®Google Scholar
• Hu C, Yang K, Li M, Huang W, Zhang F, Wang H. Lipocalin 2: a potential therapeutic target for breast cancer metastasis. Onco Targets Ther. 2018;11:8099–8106. doi:10.2147/OTT.
   PubMed Web of Science ®Google Scholar
• Jung M, Oren B, Mora J, Mertens C, Dziumbla S, Popp R, Weigert A, Grossmann N, Fleming I, Brüne B, et al. Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis. Sci Signal. 2016;9(434):ra64. doi:10.1126/scisignal.aaf3241.
   PubMed Web of Science ®Google Scholar
• Oren B, Urosevic J, Mertens C, Mora J, Guiu M, Gomis RR, Weigert A, Schmid T, Grein S, Brüne B, et al. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J Pathol. 2016;239(3):274–285. doi:10.1002/path.4724.
   PubMed Web of Science ®Google Scholar
• Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2011;226:309–314. doi:10.1002/jcp.22403.
   PubMed Web of Science ®Google Scholar
• Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009;69:8579–8584. doi:10.1158/0008-5472.CAN-09-1934.
   PubMed Web of Science ®Google Scholar
• Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009;106:3913–3918. doi:10.1073/pnas.0810617106.
   PubMed Web of Science ®Google Scholar
• Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773–789. doi:10.1038/s41577-018-0066-7.
   PubMed Web of Science ®Google Scholar
• Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15:210. doi:10.1186/bcr3436.
   PubMed Web of Science ®Google Scholar
• Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy. 2017;9:347–360. doi:10.2217/imt-2016-0141.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 2017;28:388–397. doi:10.1016/j.tem.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Bartsch DK, Gercke N, Strauch K, Wieboldt R, Matthai E, Wagner V, Rospleszcz S, Schäfer A, Franke F, Mintziras I, et al. 2018. The combination of MiRNA-196b, LCN2, and TIMP1 is a potential set of circulating biomarkers for screening individuals at risk for familial pancreatic cancer. J Clin Med. 7. DOI:10.3390/jcm7100295.
   Web of Science ®Google Scholar
• Dokun OY, Florl AR, Seifert HH, Wolff I, Schulz WA. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. Int J Cancer. 2008;123:2798–2807. doi:10.1002/ijc.23893.
   PubMed Web of Science ®Google Scholar
• Meka P, Jarjapu S, Nanchari SR, Vishwakarma SK, Edathara PM, Gorre M, Cingeetham A, Vuree S, Annamaneni S, Dunna NR, et al. LCN2 promoter methylation status as novel predictive marker for microvessel density and aggressive tumor phenotype in breast cancer patients. Asian Pac J Cancer Prev. 2015;16:4965–4969. doi:10.7314/APJCP.2015.16.12.4965.
   PubMedGoogle Scholar
• Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E. LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol. 2013;6:99–103. doi:10.1593/tlo.12373.
   PubMed Web of Science ®Google Scholar
• Cheng G, Sun X, Wang J, Xiao G, Wang X, Fan X, Zu L, Hao M, Qu A, Mao Y, et al. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2. Cancer Res. 2014;74:862–872. doi:10.1158/0008-5472.CAN-13-2420.
   PubMed Web of Science ®Google Scholar
• Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics. 2016;6:1–13. doi:10.7150/thno.12167.
   PubMed Web of Science ®Google Scholar
• Guo P, Yang J, Huang J, Auguste DT, Moses MA. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proc Natl Acad Sci U S A. 2019;116:18295–18303. doi:10.1073/pnas.1904697116.
   PubMed Web of Science ®Google Scholar
• Meade KJ, Sanchez F, Aguayo A, Nadales N, Hamalian SG, Uhlendorf TL, Banner LR, Kelber JA. Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung. Oncotarget. 2019;10:3027–3039. doi:10.18632/oncotarget.v10i32.
   PubMedGoogle Scholar
• Kurozumi S, Alsaeed S, Orah N, Miligy IM, Joseph C, Aljohani A, Toss MS, Fujii T, Shirabe K, Green Ar, et al. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Res Treat. 2020;179:557–564.
   Web of Science ®Google Scholar
• Abrahamson M. Cystatins. Methods Enzymol. 1994;244:685–700.
   PubMed Web of Science ®Google Scholar
• Ochieng J, Chaudhuri G. Cystatin superfamily. J Health Care Poor Underserved. 2010;21:51–70. doi:10.1353/hpu.0.0257.
   PubMed Web of Science ®Google Scholar
• Turk B, Stoka V. Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett. 2007;581:2761–2767. doi:10.1016/j.febslet.2007.05.038.
   PubMed Web of Science ®Google Scholar
• Benchoua A, Braudeau J, Reis A, Couriaud C, Onteniente B. Activation of proinflammatory caspases by cathepsin B in focal cerebral ischemia. J Cereb Blood Flow Metab. 2004;24:1272–1279. doi:10.1097/01.WCB.0000140272.54583.FB.
   PubMed Web of Science ®Google Scholar
• Gora J, Latajka R. Involvement of cysteine proteases in cancer. Curr Med Chem. 2015;22:944–957. doi:10.2174/0929867321666141106115624.
   PubMed Web of Science ®Google Scholar
• Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res. 1997;3:1815–1822.
   PubMed Web of Science ®Google Scholar
• Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, Bjartell A. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One. 2009;4:e7953. doi:10.1371/journal.pone.0007953.
   PubMed Web of Science ®Google Scholar
• Nakabayashi H, Hara M, Shimuzu K. Clinicopathologic significance of cystatin C expression in gliomas. Hum Pathol. 2005;36:1008–1015. doi:10.1016/j.humpath.2005.06.021.
   PubMed Web of Science ®Google Scholar
• Yan Y, Fan Q, Wang L, Zhou Y, Li J, Zhou K. LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cells. Oncotarget. 2017;8:35750–35760. doi:10.18632/oncotarget.16189.
   PubMedGoogle Scholar
• Jin K, Park S, Teo WW, Korangath P, Cho SS, Yoshida T. HOXB7 is an ERalpha cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov. 2015;5:944–959. doi:10.1158/2159-8290.CD-15-0090.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Cancer Genome AN. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Silveira HCS, Vidal DO, Burnette A, Eschbacher J, et al. The immune landscape of cancer. Immunity. 2018;48:812–30 e14. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Thorsson V, Gibbs DL, Brown SD, Wolf D, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar